Targeted drugs for metastatic renal cell carcinoma.
D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D003365:Costs and Cost Analysis; D004311:Double-Blind Method; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D011758:Pyrroles / Q000627:therapeutic use; D011994:Recombinant Proteins; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077210:Sunitinib; D016019:Survival Analysis; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007211:Indoles; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011758:Pyrroles; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; C401859:temsirolimus; D000077210:Sunitinib; D020123:Sirolimus